BOLD on XNAS, Health Care, Boundless Bio, Inc., job postings
Measures activity, not value. Not investment advice.
Shares up 109% in a year while insiders bought $736K and short interest is 20 times last year's level.
BadNet loss $55.5M over 12 months against cash of $62.9M
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $5.4M.
31 Mar 2023RevenueNet incomeNet losstallest bar $23.7M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
–
-$5.4M
30 Jun 2026
–
-$23.7M
31 Mar 2026
–
-$13.6M
31 Dec 2025
–
-$12.9M
30 Sep 2025
–
-$13.9M
30 Jun 2025
–
-$15.7M
31 Mar 2025
–
-$15.8M
31 Dec 2024
–
-$16.4M
30 Sep 2024
–
-$16.5M
30 Jun 2024
–
-$17.0M
31 Mar 2024
–
-$15.4M
31 Dec 2023
–
-$12.1M
30 Sep 2023
–
-$13.2M
30 Jun 2023
–
-$12.4M
31 Mar 2023
–
-$11.7M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
–
–
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
–
+11%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$55.5M
-$61.8M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
-$2.46
-$2.66
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
–
–
73.2%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
–
–
-25.0%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
–
–
-18.2%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-64.6%
-58.8%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
–
-$52.7M
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$62.9M
$117.6M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$0
$0
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$62.9M (net cash)
-$117.6M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.0
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$2.61
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
19.3
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
–
5.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
–
5.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
0.89
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider buy/sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
+$681K
bought $736K, sold $54K
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+5.0%
42 13F filers vs 40
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
66%
15.5M shares held by 13F filers (30 Sep 2026) of 23.6M outstanding (6 Nov 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
3.3%
790K shares sold short (30 Oct 2026) of 23.6M outstanding (6 Nov 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
5.1
790K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
+0.2%
788K shares sold short in the report before, 790K on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
7.3%
7.3% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 31%
News iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
20
20 articles in the last 7 days; its usual week has 0 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
–
20 articles in the last 7 days; its usual week has 0: fewer than one, so there is nothing to compare with.
Unusual now sharp changes in the last 90 days, compared with its own past
Short interest 790K, 20× a year earlier
Price $2.32 on 20 Nov 2026, +109% over 12 months (12-month range $1.05 to $3.00)
Sharp change
8-K and other filings
Insider net buying (open market). Insiders bought a net $2.2M in the last 12 months (the 12 months before: $0).Capital spending per quarter. Capital spending $38K in the latest quarter, -21% on a year earlier.Institutional holders (13F filers). 42 13F filers reported holding it in the latest 13F quarter, +27% on a year earlier.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, revenue per quarter, federal obligations, lobbying spend, workers in warn layoff notices.
Quarter ended 31 Mar 2023: $86K; public on 14 May 2024
Quarter ended 30 Jun 2023: $128K; public on 13 Aug 2024
Quarter ended 30 Sep 2023: $151K; public on 8 Nov 2024
Quarter ended 31 Dec 2023: $268K; public on 28 Mar 2025
Quarter ended 31 Mar 2024: $83K, -3.5% on a year earlier; public on 14 May 2024
Quarter ended 30 Jun 2024: $1.5M, +1075% on a year earlier; public on 13 Aug 2024
Quarter ended 30 Sep 2024: $483K, +220% on a year earlier; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $466K, +74% on a year earlier; public on 28 Mar 2025
Quarter ended 31 Mar 2025: $59K, -29% on a year earlier; public on 10 May 2025
Quarter ended 30 Jun 2025: $48K, -97% on a year earlier; public on 6 Aug 2025
Quarter ended 30 Sep 2025: $15K, -97% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Mar 2026: $8K, -86% on a year earlier; public on 9 May 2026
Quarter ended 30 Jun 2026: $38K, -21% on a year earlier; public on 8 Aug 2026
Institutional holders (13F filers)
31 Mar 2024 report: 41; public on 15 May 2024
30 Jun 2024 report: 45; public on 14 Aug 2024
30 Sep 2024 report: 53; public on 14 Nov 2024
31 Dec 2024 report: 55; public on 14 Feb 2025
31 Mar 2025 report: 52; public on 15 May 2025
30 Jun 2025 report: 42; public on 14 Aug 2025
30 Sep 2025 report: 33; public on 14 Nov 2025
31 Dec 2025 report: 35; public on 17 Feb 2026
31 Mar 2026 report: 36; public on 15 May 2026
30 Jun 2026 report: 40; public on 14 Aug 2026
30 Sep 2026 report: 42; public on 16 Nov 2026
What is unusual now
Made public in the last 90 days: it had 790K shares sold short in the 30 Oct 2026 report, 20× the same report last year; it also had 788K shares sold short in the 15 Oct 2026 report, 5.8× the same report last year. 6 sharp changes in all.
Short interest spike: had 790K shares sold short in the 30 Oct 2026 report, 20× the same report last year Public on 11 Nov 2026.
In 12 months: 2 director or officer changes, 2 major agreements, 1 agreement ended, 1 restructuring. Results releases and routine reports are left out.
had 790K shares sold short in the 30 Oct 2026 report, 20× the same report last year.
Same report last year: 40K; its normal report is 58K.
See the evidence
This period
790K (the 30 Oct 2026 report)
Normal report (median of 24 earlier)
58K
Typical spread (median absolute deviation)
51K
How far from its usual level
+9.7
Same report last year
40K
History used
3,227 days
the 30 Oct 2026 report24 earlier reportsnormal: 58K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 788K shares sold short in the 15 Oct 2026 report, 5.8× the same report last year.
Same report last year: 137K; its normal report is 58K.
See the evidence
This period
788K (the 15 Oct 2026 report)
Normal report (median of 24 earlier)
58K
Typical spread (median absolute deviation)
51K
How far from its usual level
+9.7
Same report last year
137K
History used
3,212 days
the 15 Oct 2026 report24 earlier reportsnormal: 58K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 778K shares sold short in the 30 Sep 2026 report, 6.1× the same report last year.
Same report last year: 127K; its normal report is 58K.
See the evidence
This period
778K (the 30 Sep 2026 report)
Normal report (median of 24 earlier)
58K
Typical spread (median absolute deviation)
51K
How far from its usual level
+9.6
Same report last year
127K
History used
3,197 days
the 30 Sep 2026 report24 earlier reportsnormal: 58K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 812K shares sold short in the 15 Sep 2026 report, 9.2× the same report last year.
Same report last year: 88K; its normal report is 58K.
See the evidence
This period
812K (the 15 Sep 2026 report)
Normal report (median of 24 earlier)
58K
Typical spread (median absolute deviation)
48K
How far from its usual level
+10.7
Same report last year
88K
History used
3,182 days
the 15 Sep 2026 report24 earlier reportsnormal: 58K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 813K shares sold short in the 31 Aug 2026 report, 12× the same report last year.
Same report last year: 68K; its normal report is 58K.
See the evidence
This period
813K (the 31 Aug 2026 report)
Normal report (median of 24 earlier)
58K
Typical spread (median absolute deviation)
44K
How far from its usual level
+11.6
Same report last year
68K
History used
3,167 days
the 31 Aug 2026 report24 earlier reportsnormal: 58K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 689K shares sold short in the 14 Aug 2026 report, 7.5× the same report last year.
Same report last year: 92K; its normal report is 58K.
See the evidence
This period
689K (the 14 Aug 2026 report)
Normal report (median of 24 earlier)
58K
Typical spread (median absolute deviation)
38K
How far from its usual level
+11.1
Same report last year
92K
History used
3,150 days
the 14 Aug 2026 report24 earlier reportsnormal: 58K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Not listed: 30 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001782303
Ticker
BOLD
Domain
boundlessbio.com
Hq location
CA|LA JOLLA|92037 (1 unverified)
Name
Boundless Bio, Inc.
Wikidata
Q104481180
SEC Form 13F institutional holdings99 data points31 Mar 2024 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)40 records12 Mar 2020 to 10 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)205 data points31 Dec 2022 to 6 Nov 2026
SEC Form 4 insider transactions20 records, 64 data points4 Apr 2024 to 20 Nov 2026
FINRA short interest (twice monthly)335 data points29 Dec 2017 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)2064 data points1 Aug 2018 to 20 Nov 2026